Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04894643
Other study ID # PARC-MA-062019
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 14, 2020
Est. completion date December 31, 2026

Study information

Verified date April 2024
Source EBG MedAustron GmbH
Contact Piero Fossati, M.D.
Phone +43 664 80878
Email piero.fossati@medaustron.at
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an interventional, single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and surgery (when feasible) for patients with borderline resectable pancreatic cancer.


Description:

This is an interventional, single arm, open label, feasibility trial of preoperative chemotherapy + concomitant chemo-proton therapy followed by surgery (when feasible) for patients with borderline resectable pancreatic cancer. Aim of this study is to test referral and enrollment procedures as well as technical feasibility. Proton therapy will be delivered in MedAustron, which is a stand alone facility. Pancreatic cancer patients are typically complex cases that require multidisciplinary care. Moreover delivery of high dose of proton therapy to large volumes including the upper abdomen lymphnodes and pancreatic neural plexus is technically challenging, therefore a feasibility study is deemed necessary. Following this study, a larger study will be performed aiming to confirm the ability of preoperative chemotherapy + concomitant chemo-proton therapy to improve resectability and ultimately outcome of borderline resectable pancreatic cancer without increase in toxicity.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 31, 2026
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with histologically or cytologically confirmed diagnosis of pancreatic cancer - Diagnosis of borderline resectable cancer according to the international consensus definition 2017. - Negative staging for distant metastasis - Blood test within the following limits absolute neutrophil count > 1,500 cells/mm³, platelet count > 100,000 cells/mm³, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) < 2.5 times the upper limit of normal, total bilirubin < 2.5 times the upper limit of normal if patient had recent biliary stenting, total bilirubin < 1.5 times the upper limit of normal if no biliary stenting was done, serum creatinine within normal range (0.6-1.5 mg/dl) with a creatinine clearance > 30 ml/min (as estimated by Cockroft Gault equation) - Age > 18 years - Karnofsky index = 70 - No tumor infiltration of stomach or duodenum - The patient is informed of the diagnosis and is able to give informed consent (Ability of subject to understand character and individual consequences of the study protocol) - Women of fertile age must have adequate conception prevention measures and must not breast feed - Signed Informed Consent (must be available before study inclusion) Exclusion Criteria: - Non-exocrine tumors - Major medical or psychiatric comorbidities that contraindicate radiation therapy, chemotherapy or surgery - Presence of distant metastasis - Pregnancy or unwilling to do adequate conception prevention - Lactating and unwilling to discontinue lactation - Men of childbearing potential not willing to use effective means of contraception - Known allergic/hypersensitivity reaction to any of the components of study treatments - Previous diagnosis of another neoplasm with worse prognosis as compared with the one in this study - Metallic prosthesis or other condition that prevent an adequate imaging for target volume definition - Loco-regional conditions that contraindicate radiotherapy e.g. active infections in the area - Previous abdominal radiotherapy - Prior systemic treatment for pancreatic cancer - Hypersensitivity to PACLitaxel, albumin, gemcitabine or to any of the excipients of the chemotherapy - Severe hepatic impairment - Baseline Neutrophil Counts < 1.5 x 10^9/L - Baseline Grade = 2 sensory or motor neuropathy - Patient refusal

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Proton Ions
According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
Drug:
Nab-PACLitaxel
Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy. It will be administered as intra venous infusion over 30 minutes.
Gemcitabine
Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy. Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel.
Capecitabine
Concomitant to proton-radiotherapy (on the same days, within week 14-19)
Procedure:
Surgical resection of the pancreas (when feasible)
Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.

Locations

Country Name City State
Austria Department of Surgery, LK Wiener Neustadt Wiener Neustadt
Austria EBG MedAustron GmbH Wiener Neustadt Niederösterreich

Sponsors (2)

Lead Sponsor Collaborator
EBG MedAustron GmbH Landesklinkum Wiener Neustadt

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity - Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Incidence of CTCAE version 5.0 Grade 4 non hematological toxicity from enrollment to six months after surgery from enrollment to six months after surgery
Primary Perioperative Mortality and Complications Incidence of 90-days-perioperative mortality and incidence of Clavien Dindo Grade III complication rate during hospitalization 90 days postoperatively
Secondary Toxicity - CTCAE v5.0 CTCAE V5.0 toxicity from enrollment to six month after surgery from enrollment to six months after surgery
Secondary Tumor recurrence local and loco-regional (i.e. in-field) tumor recurrence 260 weeks after therapy
Secondary Progression free survival loco-regional progression-free survival 260 weeks after therapy
Secondary Overall survival Overall survival 282 weeks
Secondary Pathologic tumor response Assessment of pathologic tumor response to pre-operative combined proton- chemotherapy (R0 margin and N0, degree of tumor cell necrosis in the resected tumor specimen) 260 weeks
Secondary Radiologic response Assessment of radiologic response of pre-operative chemoradiotherapy. Response to preoperative treatment will be scored with the Japan Pancreas Society (JPS) classification which is a synthesis from the Evans and College of American Pathologists classification (Grade 1: poor or no response to Grade 4: complete response) 263 weeks after proton therapy
Secondary Quality of Life questionnaire: Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep) Patient reported Quality of Life (for assessing disease-related symptoms and health-related quality of life). The higher the score the better the Quality of Life. 282 weeks
Secondary Quality of Life questionnaire: European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-30) Questionnaire developed to assess the quality of life of cancer patients. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / quality of life (QoL) represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. 282 weeks
Secondary Quality of Life questionnaire: Brief Pain Inventory The Brief Pain Inventory (BPI) is a measurement tool for assessing clinical pain.The interference items were now presented with 0-10 scales, with 0=no interference and 10=interferes completely. 282 weeks
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study